Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells

Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, however, it is known that tumors acquired resistance and eventually became even more aggressive and infiltrative after treatment. In the present study we aimed to unravel the potential cellular mechanisms of resistance to Bev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Miranda-Gonçalves, Vera, Cardoso-Carneiro, Diana, Valbom, Inês, Cury, Fernanda Paula, Silva, Viviane Aline, Granja, Sara, Reis, Rui M., Baltazar, Fátima, Martinho, Olga
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732757/
https://ncbi.nlm.nih.gov/pubmed/29262591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados